Previous 10 | Next 10 |
Syneos Health ( NASDAQ: SYNH ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is $1.19 (+22.7% Y/Y) and the consensus Revenue Estimate is $1.39B (+8.6% Y/Y). Over the last 2 years, SYNH has beaten E...
OTCQX:ACDVF , AINV , AME , AQUA , ARNC , ATKR , AUDC , BLD , BP , BPMC , CAT , CMI , CNP , CWEN , CZOO , DBD , DD , DEA , DSKE , ENTG , EOLS , EOSE , ESPR , ETN , ETRN , EXPD , OTCPK:...
MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial results on Tuesday, August 2, 2022, prior to its earnings call at 9:00 a.m. ET. ...
Syneos presents us with the economic pillars to absorb macroeconomic headwinds on the horizon. However, the market looks to have observed its profitability strengths and may have discounted this already. Valuations are unsupportive, and we've priced Syneos at $66/share. Here a...
Southeastern’s 13F portfolio value decreased from $5.96B to $5.66B this quarter. The number of positions increased from 33 to 35. Southeastern Asset Management increased IAC/InterActiveCorp and Affiliated Managers Group while decreasing Williams Companies. The top three pos...
MORRISVILLE, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Kasey Boynton, MPH, MBA, Director, Client Engagement, Real World Evidence & Late Phase, and Feni Komline, ...
No Rating Change. Medpace remains an attractive business selling at a discount to its intrinsic value. Management is aggressively repurchasing shares, a signal of confidence and a boost to EPS. For further details see: Medpace Holdings: Update Following Q1 FY2022 Earning...
IQVIA has the potential to outperform the market in a higher inflation environment. Significant growth potential with projected 17.72% FCF and 11.68% EBIT CAGR over the next 5 years. Decentralized clinical trials, the emergence of virtual trials, blockchain technologies, AI and ML...
Syneos Health, Inc. (SYNH) Q1 2022 Earnings Conference Call April 29, 2022 8:00 AM ET Company Participants Ronnie Speight - SVP, IR Alistair Macdonald - CEO Michelle Keefe - CEO Jason Meggs - CFO Michael Brooks - Chief Operating Officer Conference Call Participants Eric Coldwell - Baird Casey...
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Syneos Health, Inc. 2022 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...